Business

Definium Therapeutics’ LSD-Based Psych Drug Scores Again

Published

2 hours ago

on

Definium Therapeutics (DFTX) unveiled the second of two positive Phase 3 studies for its LSD-based drug. The biotech stock surged on the results. Patients with generalized anxiety disorder, or GAD, showed a 5.4-point improvement compared with a placebo on the 56-point Hamilton Anxiety Rating Scale. That beat the 4-point improvement investors had been hoping to see, RBC Capital Markets analyst…

Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

Related Topics:

You must be logged in to post a comment Login

Leave a Reply

Cancel reply

Trending

Exit mobile version